Oral Semaglutide Tablets

Key Launch Dates & Patent Expiry

Patent Expiry (India)

• The core semaglutide patent in India is set to expire in March 20th 2026, which opens the market for generic versions by Indian companies, including Sun Pharma.

• Torrent Pharmaceuticals obtained clearance for oral semaglutide  tablets in strengths of 3 mg, 7 mg, and 14 mg (synthetic origin), also based on phase III study results.

 1. Noveltreat – Weight-Loss Semaglutide Injection

What it is

• A generic version of Wegovy (semaglutide) designed for chronic weight management in adults.

Brand Name

• Noveltreat — the Indian brand under which Sun Pharma’s semaglutide will be sold for weight loss.

Expected India Release

• Scheduled to launch after the semaglutide patent expires in March 2026.

Dosing Formats

• Will be available in various strengths similar to Wegovy (e.g., 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg weekly pens).

 2. Sematrinity – Type-2 Diabetes Semaglutide Injection

What it is

• A generic injectable semaglutide aimed at type 2 diabetes treatment, similar to Ozempic.

Brand Name

• Sematrinity — Sun Pharma’s semaglutide product for diabetes after patent expiry.

Expected India Release

• This version will also be launched after the semaglutide patent expires in March 2026, following regulatory approval.

 International (FDA / US) Status

At this time, Sun Pharma has secured regulatory clearances in India (DCGI) for its semaglutide products. However:

• No publicly confirmed US FDA approval has been announced yet for Sun Pharma’s semaglutide generics.

• Semaglutide patents in the United States are expected to last into the early 2030s, which typically delays generic launches in the U.S. until later than in India and other countries.

Because of these patents, most generics (including Sun Pharma’s) are currently planned for markets like India first, with global launches depending on when and where patents expire.